Health Condition 1: F20- Schizophrenia
Conditions
Interventions
Intervention1: aripiprazole , olanzapine: Tab. Aripiprazole 10 mg max. upto 30 mg in divided doses daily for 10 weeks.
Tab. Olanzapine 5 mg max. upto 20 mg in divided doses daily for 10 weeks.
Interve
Sponsors
Government Medical College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: . Patient or nominated representative willing for consent 2. Patient in age group of 18-50years 3. Patients diagnosed with schizophrenia according to DSM 5 criteria with total duration of illness less than 5 years 4. Patients who have never received aripiprazole and/or olanzapine in the past
Exclusion criteria
Exclusion criteria: Patients with Treatment Resistant Schizophrenia (TRS) 2. Patients with neurological disorders â?? head injury, tumours, movement disorders (except antipsychotic induced), dementia, organic brain syndromes (eg. delirium, amnesia), epilepsy. 3. Patients who have received ECT in past 3 months 4. Patients with co-morbid substance dependence (except nicotine and Caffeine) 5. Patients who are lactating or pregnant 6. Patients who received cognitive remediation in recent past. 7. Patients diagnosed with any unstable medical (hypothyroidism, diabetes insipidus, kidney disease, myasthenia gravis, chronic heart disease) or surgical disorders. 8. Patients with subnormal intelligence. 9. Actively Suicidal patients.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| scoring on PANSS, BPRS,ASEX,GAS,Timepoint: 0weeks,2weeks,4weeks,6weeks,8weeks and 10 weeks | — |
Primary
| Measure | Time frame |
|---|---|
| comparison between changes in neurocognitive profile on treatment with Aripiprazole and olanzapineTimepoint: Baseline and 10 weeks | — |
Countries
India
Contacts
Public ContactDr Sanya Sharma
Panjab University
Outcome results
None listed